Add like
Add dislike
Add to saved papers

MicroRNA-4286 promotes esophageal carcinoma development by targeting INPP4A to evoke the JAK2/STAT3 pathway activation.

Die Pharmazie 2018 June 2
This study aimed to investigate the key roles of miR-4286 in regulating the development of esophageal carcinoma, as well as its regulatory mechanism. The expression of miR-4286 in esophageal carcinoma tissues and cells was determined. Effects of abnormal expression of miR-4286 cell viability, apoptosis, migration and invasion were further investigated. Furthermore, the potential target of miR-4286 was explored, and the regulatory relationship between miR-4286 and Janus tyrosine kinase/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway was elucidated. The results showed that miR-4286 was highly expressed in esophageal carcinoma tissues and cells. Overexpression of miR-4286 significantly promoted cell viability, migration and invasion. In addition, Inositol Polyphosphate 4-Phosphatase Type I Gene (INPP4A) was a target of miR-4286. The effects of miR-4286 inhibitor on cell proliferation, migration, invasion and apoptosis were significantly counteracted by knockdown of INPP4A concurrently. Furthermore, inhibition of miR-4286 suppressed the activation of JAK2/STAT3 pathway, which was reversed after miR-4286 inhibition and INPP4A knockdown at the same time. Our findings reveal that highly expression of miR-4286 may promote the development of esophageal carcinoma by targeting INPP4A to evoke the JAK2/STAT3 pathway activation. miR-4286 may serve as a promising target for esophageal carcinoma treatment.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app